Pathways and therapeutic targets in melanoma

Emma Shtivelman1, Michael Q A Davies, Patrick Hwu

  • 1Cancer Commons, Palo Alto, CA, USA.

Oncotarget
|April 19, 2014
PubMed

Insights

Recent advances in understanding melanoma biology and genomics have revolutionized treatment, shifting focus from chemotherapy to targeted and immune therapies. Current research addresses overcoming resistance to these therapies and understanding varied responses to immunotherapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genomics

Background:

  • Metastatic melanoma historically had a poor prognosis with limited treatment options.
  • Chemotherapy offered minimal benefit for patients with advanced melanoma.
  • Recent breakthroughs in understanding melanoma's molecular underpinnings have spurred novel therapeutic strategies.

Purpose of the Study:

  • To review current knowledge on molecular pathways in melanoma.
  • To discuss the clinical relevance of these pathways in treatment.
  • To highlight advances in targeted and immune therapies for melanoma.

Main Methods:

  • Comprehensive literature review of molecular pathways in melanoma.
  • Analysis of genomic and other "omics" scale data in tumor studies.
  • Synthesis of findings on treatment advancements and resistance mechanisms.

Main Results:

  • Targeted therapies and immunotherapies have significantly improved melanoma patient prognosis.
  • Understanding of melanoma biology, driven by omics analyses, is crucial for treatment development.
  • Key challenges now include overcoming resistance to targeted treatments and explaining diverse responses to immunotherapy.

Conclusions:

  • Molecular insights have transformed melanoma treatment paradigms.
  • Future research must focus on resistance mechanisms and optimizing immune therapy efficacy.
  • Continued investigation into melanoma's complex biology is essential for further therapeutic progress.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
4.7K